Changes ahead for US list of drugs with safety concerns
This article was originally published in Scrip
The US FDAwill improve the transparency and context surrounding public disclosure of medicines that are being evaluated for safety issues. The agency "got the message" that improvements to its first quarterly listing of such products were needed, its center for drug evaluation and research's (CDER) director Dr Janet Woodcock told a drug safety conference cosponsored by the Drug Information Association, the FDA and PhRMA.
You may also be interested in...
Generic drugs program has approved almost 300 manufacturing changes to help shore up the supply chain, with some prior approval supplements being downgraded to ‘changes being effected’ supplements, FDA officials said at GDUFA III kick-off meeting.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.